Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Core Insights - Atea Pharmaceuticals has announced promising in vitro results for two oral nucleotide analogs, AT-587 and AT-2490, as potential first-in-class inhibitors for Hepatitis E virus (HEV) infection [2][3] - The company plans to initiate a Phase 1 clinical program for AT-587 in mid-2026, focusing on treating immunocompromised patients with chronic HEV infections [4][5] Company Overview - Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company dedicated to developing oral antiviral therapies for serious viral diseases [7] - The company utilizes a proprietary nucleos(t)ide prodrug platform to create novel product candidates targeting single-stranded RNA viruses [7] Research Findings - In vitro studies revealed that AT-587 and AT-2490 are 30-150 times more potent against HEV compared to existing treatments like sofosbuvir and ribavirin [3] - Both compounds demonstrated antiviral activity in human liver cells without showing any toxicity [3] Market Need - There is currently no approved antiviral therapy for HEV, highlighting a significant unmet medical need, especially for immunocompromised patients at risk of rapid progression to cirrhosis [5][6] - HEV is a global health concern with an estimated 20 million infections annually, particularly affecting vulnerable populations [6]